[go: up one dir, main page]

WO2003016559A3 - Method for treating diabetes based on the modulation of nh4alpha gene expression - Google Patents

Method for treating diabetes based on the modulation of nh4alpha gene expression Download PDF

Info

Publication number
WO2003016559A3
WO2003016559A3 PCT/DK2002/000537 DK0200537W WO03016559A3 WO 2003016559 A3 WO2003016559 A3 WO 2003016559A3 DK 0200537 W DK0200537 W DK 0200537W WO 03016559 A3 WO03016559 A3 WO 03016559A3
Authority
WO
WIPO (PCT)
Prior art keywords
nh4alpha
modulation
hnf4α
gene expression
treating diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2002/000537
Other languages
French (fr)
Other versions
WO2003016559A2 (en
Inventor
Stepanka Pruhova
Jan Lebl
Silvia Fernandez Boj
Torben Hansen
Sara Kristine Frederiksen
Maria Lajer Jensen
Oluf Borby Pedersen
Marcelina Parrizas
Miguel Angel Maestro
Jorge Pedro Ferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Fundacio Clinic per a la Recerca Biomedica FCRB
Original Assignee
Novo Nordisk AS
Fundacio Clinic per a la Recerca Biomedica FCRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Fundacio Clinic per a la Recerca Biomedica FCRB filed Critical Novo Nordisk AS
Priority to AU2002325821A priority Critical patent/AU2002325821A1/en
Publication of WO2003016559A2 publication Critical patent/WO2003016559A2/en
Publication of WO2003016559A3 publication Critical patent/WO2003016559A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention regards a screening method for screening for modulators of the expression of hnf4α from the hnf4α P2 promoter region, which method comprises the steps of obtaining a transcription reporter system comprising a nucleotide construct comprising a reporter gene under control of the hnf4α P2 promoter reg ion corresponding to nucleotide 1 to 1447 of the sequence shown in the Sequence listing as SEQ ID No. 1 or a fragment thereof, contacting the transcription reporter system with a putative modulator and assaying for a change in the level of expression of the reporter gene.
PCT/DK2002/000537 2001-08-17 2002-08-15 Method for treating diabetes based on the modulation of nh4alpha gene expression Ceased WO2003016559A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002325821A AU2002325821A1 (en) 2001-08-17 2002-08-15 Method for treating diabetes based on the modulation of nh4alpha gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01610085.1 2001-08-17
EP01610085 2001-08-17

Publications (2)

Publication Number Publication Date
WO2003016559A2 WO2003016559A2 (en) 2003-02-27
WO2003016559A3 true WO2003016559A3 (en) 2003-10-16

Family

ID=8183557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000537 Ceased WO2003016559A2 (en) 2001-08-17 2002-08-15 Method for treating diabetes based on the modulation of nh4alpha gene expression

Country Status (2)

Country Link
AU (1) AU2002325821A1 (en)
WO (1) WO2003016559A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
EP1712641A1 (en) * 2005-04-14 2006-10-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Use of novel HNF4a target genes and their gene products
EP4041894A1 (en) * 2019-09-23 2022-08-17 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187533B1 (en) * 1996-09-10 2001-02-13 Arch Development Corporation Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187533B1 (en) * 1996-09-10 2001-02-13 Arch Development Corporation Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 10 September 1999 (1999-09-10), XP002192981 *
FURUTA HIROTO ET AL: "Organization and partial sequence of the hepatocyte nuclear factor-4-alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY.", DIABETES, vol. 46, no. 10, 1997, pages 1652 - 1657, XP001064298, ISSN: 0012-1797 *
LAUSEN JOERN ET AL: "Naturally occurring mutations in the human HNF4alpha gene impair the function of the transcription factor to a varying degree.", NUCLEIC ACIDS RESEARCH., vol. 28, no. 2, 15 January 2000 (2000-01-15), pages 430 - 437, XP002192980, ISSN: 0305-1048 *
MOLLER ANN M ET AL: "A novel Phe75fsdelT mutation in the hepatocyte nuclear factor-4alpha gene in a Danish pedigree with maturity-onset diabetes of the young.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 1, January 1999 (1999-01-01), pages 367 - 369, XP001064367, ISSN: 0021-972X *
NAKHEI HASSAN ET AL: "An alternative splice variant of the tissue specific transcription factor HNF4alpha predominates in undifferentiated murine cell types.", NUCLEIC ACIDS RESEARCH, vol. 26, no. 2, 15 January 1998 (1998-01-15), pages 497 - 504, XP002192978, ISSN: 0305-1048 *

Also Published As

Publication number Publication date
WO2003016559A2 (en) 2003-02-27
AU2002325821A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
DE69434663D1 (en) NUCLEOTIDE SEQUENCES FOR CONTROLLING THE EXPRESSION OF DNA SEQUENCES IN A CELLULAR HOST
AU2733895A (en) A fungus wherein the area gene has been modified and an area gene from aspergillus oryzae
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
PL1824977T3 (en) Promoter nucleic acid derived from Corynebacterium genus , expression cassette comprising the promoter and vector , host cell comprising the vector , vector and method for expressing a gene using the cell .
EP1197567A3 (en) Characterisation of gene function using double stranded RNA inhibition
WO2004101759A3 (en) Novel lipolytic enzyme lip2
WO2001019981A3 (en) Functional genomics using zinc finger proteins
WO2004101760A3 (en) Novel lipolytic enzyme elip
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2001036641A3 (en) DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
EP0892048A3 (en) XAF genes and polypeptides and their use for modulating apoptosis
WO2003016559A3 (en) Method for treating diabetes based on the modulation of nh4alpha gene expression
WO2004074448A3 (en) mTOR KINASE-ASSOCIATED PROTEINS
WO2001016317A3 (en) Polycyclic aromatic hydrocarbon induced molecules
AU1727597A (en) Purified sr-p70 protein
WO2003020887A3 (en) Gene identification
WO1997020928A1 (en) Novel semaphorin z and gene encoding the same
WO2003033692A3 (en) Use of the adenoviral e2 late promoter
ATE219515T1 (en) METHODS AND REAGENTS FOR REGULATING APOPTOSIS
WO2001048185A3 (en) Transcription regulatory sequences derived from chlamydomonas reinhardtii
WO2004019283A3 (en) Methods for regulating transcription by targeting quadruplex dna
WO2000003026A3 (en) Transcription coactivators
WO2001077380A3 (en) Method for predicting predisposition to a disease associated with mutations in a rpgr gene
WO2003048767A3 (en) Use of elavl-1 gene in the detection and modulation of apoptosis
EP0897008A3 (en) His5

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP